← Leaderboards
Markus D Siegelin
Columbia University Health Sciences
$6,883,771
Attributed
$6,883,771
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $891K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,883,771 · 5
By mechanism
R01$5,493,496 · 3
K08$937,900 · 1
R21$452,375 · 1
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- David H Sachs$52,326,282
- Alice S Prince$23,300,807
- Martin Stute$459,849
- Vadim S Ten$8,673,722
- Alexander Galkin$3,351,788
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMalignant Neoplasm Of BrainIn VitroGlioblastomaIn VivoPrimary Brain NeoplasmsUnited StatesDiagnosisTumorGliomaMediatingApoptosisLife ExpectancyTreatment StrategyBrain NeoplasmsInnovationAdultMitochondriaBiological ModelsCombatGeneticCombined Modality TherapyPathway InteractionsCell Death
Grant awards (22)
HDAC Inhibitors Reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma$364,500
R01 · FY2025 · NS · contact PI
Targeting OGDH for Glioblastoma Therapy$205,625
R21 · FY2025 · NS · contact PI
HDAC Inhibitors Reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma$392,850
R01 · FY2024 · NS · contact PI
Targeting OGDH for Glioblastoma Therapy$246,750
R21 · FY2024 · NS · contact PI
HDAC inhibitors reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma$405,000
R01 · FY2023 · NS · contact PI
HDAC inhibitors reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma$405,000
R01 · FY2022 · NS · contact PI
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas$354,375
R01 · FY2022 · NS · contact PI
HDAC inhibitors reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma$405,000
R01 · FY2021 · NS · contact PI
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas$354,375
R01 · FY2021 · NS · contact PI
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas$354,375
R01 · FY2020 · NS · contact PI
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.$350,000
R01 · FY2020 · NS · contact PI
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas$354,375
R01 · FY2019 · NS · contact PI
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.$350,000
R01 · FY2019 · NS · contact PI
Targeting Mutant IDH1 for a Novel Synthetic Lethal Interaction in Malignant Gliomas$353,646
R01 · FY2018 · NS · contact PI
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.$350,000
R01 · FY2018 · NS · contact PI
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe$187,380
K08 · FY2018 · NS · contact PI
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.$350,000
R01 · FY2017 · NS · contact PI
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe$188,380
K08 · FY2017 · NS · contact PI
Dual Inhibition of Mitochondrial Matrix Chaperones and Anti-Apoptotic Bcl-2 Family Members for Glioblastoma Therapy.$350,000
R01 · FY2016 · NS · contact PI
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe$187,380
K08 · FY2016 · NS · contact PI
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe$187,380
K08 · FY2015 · NS · contact PI
Overcoming apoptotic resistance in glioblastoma by CP-d/n-ATF5, a novel tumor spe$187,380
K08 · FY2014 · NS · contact PI